ArticleFrontiers in oncology2026
Three-dimensional exoscope-assisted combined petrosal approach for petroclival meningiomas: technical nuances from early experience.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Petroclival meningiomas (PCMs) are among the most challenging skull base tumors due to their deep location and proximity to critical neurovascular structures. The combined petrosal approach (CPA) provides wide exposure of the petroclival region, although conventional microscopic visualization may be ergonomically demanding in narrow operative corridors. The introduction of three-dimensional (3D) exoscopes offers enhanced magnification, improved ergonomics, and shared visualization. This study evaluates the feasibility and preliminary outcomes of CPA for PCM resection performed using a 4K 3D exoscope during its first year of clinical application. Methods: Three consecutive patients underwent CPA for PCM resection using the ORBEYE™ 4K 3D exoscope between December 2024 and December 2025. Clinical data included demographics, pre- and postoperative neurological deficits, complications, operative time, extent of resection, and the 3-month outcomes. Gross total resection (GTR) was defined as the absence of residual enhancing tumor on postoperative MRI, whereas subtotal resection (STR) indicates intentional residual tumor left to minimize the risk of neurological injury. Results: The mean age at surgery was 50.7 years. All patients presented with preoperative cranial nerve (CN) deficits. GTR was achieved in two cases, while one patient underwent planned STR followed by radiosurgery. The mean operative time was 9 h and 40 min. One transient postoperative CN VI palsy completely resolved within 3 months, and one patient developed pneumonia that was successfully treated during hospitalization. No intraoperative complications or mortality occurred. Conclusions: Although the limited sample precludes conclusions with regard to efficacy or superiority, our preliminary experience suggests that the 4K 3D exoscope is a feasible adjunct in CPA for PCM surgery, providing high-quality visualization and favorable early operative outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.